Swiss drug maker Novartis (NVS) said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies.
"These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR may offer benefit for acromegaly patients whose disease is not fully controlled on their current therapy. As part of our long-standing commitment to transforming the care of rare pituitary diseases, we are working to bring this potentially meaningful solution to the acromegaly community," said Alessandro Riva, president, Novartis Oncology ad interim and Global Head, Oncology Development and Medical Affairs.
Benign tumour in pituitary gland that secretes excess growth hormone leads to acromegaly that causes enlargement of body parts, including hands, feet and facial features.
The Phase III trial that was done on 198 patients examined pasireotide LAR 40 mg or pasireotide LAR 60 mg versus continued open-label treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (the control group) for 24 weeks.